Name | olmesartan medoxomil |
Synonyms | OMST cs-866 olmetec MEDOXOMIL Olmesartan Medoxomi Olmesartan MedoxomiI olmesartan medoxomil Olmesartan Medoximil OLMESARTAN MEDOXOMIL USP ORGANIC CHEMICA Olmesartan medoxomil for system suitability (5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl 1-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl] 4-yl)methyl)-4-( (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 4-ethyl-2-propyl-1-{[2'-(2H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-imidazole-5-carboxylate (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl.5-(2-hydroxypropan-2-yl)-2-propyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazole-4-carboxylate 4-(1-hydroxy-1-methylethyl)-2-propyl-1-[[2'-(1h-tetazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1h-imidazole-5-carboxylic acid (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester 2-Butyl-4-(1-hydroxy-1-methylethyl)-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-imidazole-5-carboxylic acid (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester 4-(1-HYDROXY-1-METHYLETHYL)-2-PROPYL-1-[[2'-(1H-TETRAZOL-5-YL)[1,1'-BIPHENYL]-4-YL]METHYL]-1H-IMIDAZOLE-5-CARBOXYLIC ACID (5-METHYL-2-OXO-1,3-DIOXOL-4-YL)METHYL ESTER 4-(1-hydroxy-1-methylethyl)-2-propyl-1-((2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl-1H-Imidazole-5-carboxylic acid, (5-methyl -2-oxo-1,3-dioxol-4-yl) methyl ester 1H-IMIDAZOLE-5-CARBOXYLIC ACID, 4-(1-HYDROXY-1-METHYLETHYL)-2-PROPYL-1-[[2'-(1H-TETRAZOL-5-YL)[1,1'-BIPHENYL]-4-YL]METHYL]-, (5-METHYL-2-OXO-1,3-DIOXOL-4-YL)METHYL ESTER 1H-Imidazole-5-carboxylic acid, 4-(1-hydroxy-1-methylethyl)-2-propyl-1-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester |
CAS | 144689-63-4 |
EINECS | 604-433-1 |
InChIKey | UQGKUQLKSCSZGY-UHFFFAOYSA-N |
Molecular Formula | C29H30N6O6 |
Molar Mass | 558.59 |
Density | 1.38±0.1 g/cm3(Predicted) |
Melting Point | 180°C |
Boling Point | 804.2±75.0 °C(Predicted) |
Flash Point | 180°C |
Solubility | DMSO 89 mg/mL Water <1 mg/mL Ethanol <1 mg/mL |
Appearance | White to off-white crystalline powder |
Color | white to beige |
pKa | 4.15±0.10(Predicted) |
Storage Condition | 2-8°C |
Physical and Chemical Properties | Melting point 180°C DECOMPOSITION 180°C |
Use | Antihypertensive drugs |
In vitro study | Olmesartan Medoxomil significantly reduced the content of hydroxyproline in liver, collagen α1(I) and α-smooth muscle actin (alpha-SMA) and transforming growth factor-β1 (TGF-β1) in plasma expression of mRNA. Olmesartan Medoxomil is a prodrug containing Ester moiety. After oral administration, it is rapidly cleaved to release the active form Olmesartan(RNH-6270). Olmesartan is a highly efficient, competitive and selective antagonist of all AT1 receptors, there is almost no antagonism to AT2 and AT4 receptors. |
In vivo study | In conscious rats, Olmesartan produced a rapid and long-lasting inhibition of all induced pressor responses. Oralolmesartan medoxomil also inhibited the holopressor response, but the effect was slower compared to intravenous administration. In several rat and dog models, Olmesartan showed dose-dependent antihypertensive effects, with the most pronounced effects in the high plasma renin model when compared to normal or low renin types. In addition to the parahypotensive effect, Oralolmesartan medoxomil has shown beneficial effects in various types of renal disease and heart failure animal models, and antiatherosclerotic effects in hyperlipidemic animals. In rats, Oralolmesartan medoxomil dose-dependently improved the histopathological and biochemical damage of the rat colon, an effect equivalent to or even greater than the effect of standard Sulfasalazine. In rats, Oralolmesartan medoxomil significantly reduced the induction of hypoxic cor pulmonale, not only observed in echocardiography, but also in chronic hypoxic rats brain natriuretic peptide (BNP), and reduce the induction of TGF-β and endothelin gene expression in molecular studies. |
RTECS | NI4014200 |
HS Code | 2934990002 |